

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated January 26, 2021 (the “**Prospectus**”) issued by MicroPort CardioFlow Medtech Corporation (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities by the Company in the United States.

In connection with the Global Offering, J.P. Morgan Securities (Asia Pacific) Limited, as stabilization manager (the “**Stabilization Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilization Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on Sunday, February 28, 2021, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Sunday, February 28, 2021, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



## MICROPORT CARDIOFLOW MEDTECH CORPORATION

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

### GLOBAL OFFERING

<b>Number of Offer Shares under the Global Offering</b>	<b>: 205,620,000 Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 20,562,000 Shares (subject to adjustment)</b>
<b>Number of International Offer Shares</b>	<b>: 185,058,000 Shares (including 10,281,000 Reserved Shares under the Preferential Offering) (subject to adjustment and the Over-allotment Option)</b>
<b>Maximum Offer Price</b>	<b>: HK\$12.20 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars, subject to refund)</b>
<b>Nominal Value</b>	<b>: US\$0.000005 per Share</b>
<b>Stock Code</b>	<b>: 2160</b>

*Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

**J.P.Morgan**



The Company is initially offering 205,620,000 Shares (subject to the Over-allotment Option) under the Global Offering, which consists of 20,562,000 Hong Kong Offer Shares (subject to adjustment) and 185,058,000 International Offer Shares (subject to adjustment and the Over-allotment Option), representing 10% and 90% of the total number of Shares initially available under the Global Offering, respectively. Of the 185,058,000 Offer Shares initially being offered under the International Offering, 10,281,000 Offer Shares (representing approximately 5.56% and 5% of the Offer Shares initially being offered under the International Offering and the Global Offering, respectively) will be offered to Qualifying MicroPort Shareholders as an Assured Entitlement by way of the Preferential Offering. The allocation of the Offer Shares between the International Offering and the Hong Kong Public Offering, in each case, will be subject to reallocation on the basis as described in the section headed “Structure of the Global Offering” in the Prospectus. The Reserved Shares are not subject to such reallocation. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall be not more than two times the number of Hong Kong Offer Shares initially available under the Hong Kong Public Offering (i.e. 41,124,000 Offer Shares), and the final Offer Price shall be fixed at the low end of the indicative Offer Price range (i.e. HK\$11.10 per Offer Share).

An application has been made by the Company to the Listing Committee of the Stock Exchange for the approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering (including any Shares which may be issued pursuant to the exercise of the Over-allotment Option and under the Share Option Scheme).

Subject to the granting of the approval for the listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange, or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and the CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS. Investors should seek the advice of their stockbrokers or other professional advisers for details of the settlement arrangement as such arrangements may affect their rights and interests.

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, which will be exercisable by the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) at any time from the Listing Date to the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering (being Sunday, February 28, 2021). Pursuant to the Over-allotment Option, the Company may be required to allot and issue up to 30,843,000 additional Offer Shares, representing 15% of the Offer Shares initially available under the Global Offering, at the Offer Price, to cover over-allocation in the International Offering, if any. In the event the Over-allotment Option is exercised, the number of Reserved Shares will not change.

Assuming that the Global Offering becomes unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised at or before 8:00 a.m. in Hong Kong on Thursday, February 4, 2021, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, February 4, 2021 (Hong Kong time). In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company at [www.cardioflowmedtech.com](http://www.cardioflowmedtech.com).

The Offer Price will not be more than HK\$12.20 per Offer Shares and is expected to be not less than HK\$11.10 per Offer Share unless otherwise announced as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Hong Kong Offer Shares and the Reserved Shares are required to pay, on application, the maximum Offer Price of HK\$12.20 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$12.20 per Offer Share.

**Applications for the Hong Kong Offer Shares and Reserved Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for the White Form eIPO.**

Applicants who would like to be allotted the Hong Kong Offer Shares registered in their own names should either (i) complete and sign the **WHITE** Application Forms; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) under the **White Form eIPO** service. Applicants who would like to be allotted the Hong Kong Offer Shares registered in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS participants should either (i) complete and sign the **YELLOW** Application Forms; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Qualifying MicroPort Shareholders who would like to be allotted the Reserved Shares under the Preferential Offering should complete and sign the **BLUE** Application Forms.

Members of the public and Qualifying MicroPort Shareholders may obtain a copy of the printed prospectus, together with the **WHITE** Application Form, during normal business hours from 9:00 a.m. on Tuesday, January 26, 2021 until 12:00 noon on Friday, January 29, 2021 at the following locations:

1. any of the following branches of the receiving bank for the Hong Kong Public Offering:

Bank of China (Hong Kong) Limited

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
Hong Kong Island	Des Voeux Road West Branch	111–119 Des Voeux Road West, Hong Kong
	Gilman Street Branch	136 Des Voeux Road Central, Hong Kong
Kowloon	Telford Plaza Branch	Shop Unit P2–P7, Telford Plaza, No. 33 Wai Yip Street, Kowloon Bay, Kowloon
	Mei Foo Mount Sterling Mall Branch	Shop N47–49, G/F, Mount Sterling Mall, Mei Foo Sun Chuen, Kowloon
New Territories	Tseung Kwan O Plaza Branch	Shop 112–125, Level 1, Tseung Kwan O Plaza, Tseung Kwan O, New Territories
	Kwai Chung Plaza Branch	A18–20, G/F Kwai Chung Plaza, 7–11 Kwai Foo Road, Kwai Chung, New Territories

2. any of the following offices of certain Hong Kong Underwriters:

- (a) J.P. Morgan Securities (Asia Pacific) Limited, at 28/F, Chater House, 8 Connaught Road Central, Hong Kong
- (b) China International Capital Corporation Hong Kong Securities Limited, at 29/F, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong

**Details of where printed prospectuses may be obtained will be displayed prominently at every designated branch of the receiving bank where WHITE Application Forms are distributed.**

Copies of the printed prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Tuesday, January 26, 2021 until 12:00 noon on Friday, January 29, 2021 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have such copies of application forms and the prospectus available.

The completed **WHITE** or **YELLOW** Application Form, together with a check or a banker's cashier order attached and marked payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED — MICROPORT CARDIOFLOW PUBLIC OFFER**" for the payment, should be deposited in the special collection boxes provided at any of the designated branches of the receiving bank listed above, at the following times:

**Tuesday, January 26, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Wednesday, January 27, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Thursday, January 28, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Friday, January 29, 2021 — 9:00 a.m. to 12:00 noon**

Applicants may submit applications through the **White Form eIPO** service through the designated website at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last day for applications) from 9:00 a.m. on Tuesday, January 26, 2021 until 11:30 a.m. on Friday, January 29, 2021 or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists" in the Prospectus.

A **BLUE** Application Form, and prospectus (if the related Qualifying MicroPort shareholders have elected to receive corporate communications in printed form) has been despatched to each Qualifying MicroPort Shareholder on or before Tuesday, January 26, 2021. Electronic copies of the Prospectus can be viewed from the respective websites of the Company at [www.cardioflowmedtech.com](http://www.cardioflowmedtech.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the section headed "*HKEXnews > Listed Company Publications > Latest Listed Company Information*".

Qualifying MicroPort Shareholders who require a replacement **BLUE** Application Form should contact Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or on its hotline +852 2862 8555. Printed copies of the Prospectus can be collected from the branches of the designated receiving bank or the offices of certain Hong Kong Underwriters as stated above.

The completed **BLUE** Application Form, together with a check or a banker's cashier order attached and marked payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED — MICROPORT CARDIOFLOW PREFERENTIAL OFFER**" for the payment, should be deposited in the special collection boxes provided at any of the designated branches of the receiving bank listed above, at the following times:

**Tuesday, January 26, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Wednesday, January 27, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Thursday, January 28, 2021 — 9:00 a.m. to 4:00 p.m.**  
**Friday, January 29, 2021 — 9:00 a.m. to 12:00 noon**

**CCASS Investor Participants can input electronic application instructions** from 9:00 a.m. on Tuesday, January 26, 2021 until 12:00 noon on Friday, January 29, 2021 (24 hours daily, except on Friday, January 29, 2021, the last day for applications). The latest time for inputting your **electronic application instructions** will be 12:00 noon on Friday, January 29, 2021, the last day for applications (or such later time as described in "How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists" in the Prospectus).

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares and Reserved Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the Preferential Offering and the basis of allocation of the Hong Kong Offer Shares and the Reserved Shares on Wednesday, February 3, 2021 on our website [www.cardioflowmedtech.com](http://www.cardioflowmedtech.com) and the website of the Stock Exchange [www.hkexnews.hk](http://www.hkexnews.hk).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering and the Preferential Offering will be made available at the time and date and in a manner described in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares — E. Publication of Results" in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$12.20 per Offer Share (excluding brokerage, SFC transaction levy and the Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with the section headed “Structure of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the check or banker’s cashier order will not be cleared.

The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid certificates of title at 8:00 a.m. on Thursday, February 4, 2021 (Hong Kong time) provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Assuming that the Global Offering becomes unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised at or before 8:00 a.m. in Hong Kong on Thursday, February 4, 2021, dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Thursday, February 4, 2021 (Hong Kong time). The Shares will be traded in board lots of 1,000 Shares each under the Company’s stock code 2160.

By order of the Board of Directors  
**MicroPort CardioFlow Medtech Corporation**  
**Luo Qiyi**  
*Chairman*

Hong Kong, January 26, 2021

*As at the date of this announcement, the executive Directors are Mr. Chen Guoming, Ms. Yan Luying and Mr. Wu Guojia, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Jiang Hualiang and Ms. Sun Zhixiang.*